Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 15 of 24, showing 5 Applications out of 119 total, starting on record 71, ending on 75

# Protocol No Study Title Investigator(s) & Site(s)

71.

ECCT/16/02/06   A study of the safety and immune response of 2 doses of a new Shigella vaccine in Kenyan adults.
    A Phase 2a, observer blind, randomized, controlled, Single Center Study to evaluate the Safety, Reactogenicity and Immunogenicity of 2 doses of the GVGH 1790GAHB Vaccine against Shigella sonnei, administered intramuscularly in Adult Subjects from a country endemic for shigellosis [GVGH study H03_04TP]   
Principal Investigator(s)
1. Christina Wesonga Obiero
Site(s) in Kenya
Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme
 
View

72.

ECCT/11/10/05  
    A Phase 3, Open Label, Randomized, Comparative Study to Evaluate Azithromycin Plus Chloroquine and Sulfadoxine Plus Pyrimethamine Combinations for Intermittent Preventive Treatment of Falciparum Malaria Infection in Pregnant Women in Africa. WRAIR #1775, KEMRI SSC #1983   
Principal Investigator(s)
1. Lucas Otieno Tina
Site(s) in Kenya
1. KEMRI/WRP Kombewa (Kisumu county)
 
View

73.

ECCT/20/05/01   ChAdOx1 nCoV-19 trial
    A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya   
Principal Investigator(s)
1. George Warimwe
Site(s) in Kenya
KEMRI-CGMRC
 
View

74.

ECCT/23/06/02   IMAGINE-TBM
    A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM).   
Principal Investigator(s)
1. Deborah Chepng\'eno Langat
Site(s) in Kenya
KEMRI/WRP CRC
 
View

75.

ECCT/23/05/02   A5384
    A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM)   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
 
View